Bone Cancer Diagnosis Market Size to Reach USD 2.20 Billion by 2035 as AI Imaging and Molecular Testing Expand

According to DataM Intelligence, the global bone cancer diagnosis market size reached USD 1.33 billion in 2025 and is projected to reach approximately USD 2.20 billion by 2035, growing at a CAGR of 5.2% during the 2026-2035 forecast period. This trajectory places the bone cancer diagnostic market on a path of steady, mid-single-digit growth over the coming decade, supported by a diagnostic pathway that typically requires several sequential technologies rather than a single test.
The bone cancer diagnosis market's growth is being shaped by a shift from purely morphological assessment toward more technologically layered diagnosis. Artificial intelligence is beginning to move from research settings into regulated clinical use for bone-lesion detection, while sarcoma classification is increasingly dependent on molecular and genetic testing rather than imaging or pathology alone. Ewing sarcoma illustrates this shift clearly, as its diagnosis is progressively defined by specific gene fusions rather than appearance under the microscope.
Get More About This Market Research Report: https://www.datamintelligence.com/research-report/bone-cancer-diagnosis-market?akash

Recent Developments
• NCI Osteosarcoma Study Update (July 2026): The NCI-sponsored Phase II/III osteosarcoma trial evaluating cabozantinib with chemotherapy remained recruiting, with the protocol incorporating ctDNA measurements at diagnosis and throughout therapy to assess prognostic and treatment-response value.
• Wake Forest Liquid Biopsy Study (July 2026): A Wake Forest-led prospective study remained recruiting, continuing to evaluate low-pass whole-genome sequencing for ctDNA detection across adult and pediatric bone and soft-tissue sarcomas.
• Philips Titanion Research Platform (May 2026): Philips introduced its Titanion ultra-high-gradient 3.0T MRI research platform, designed for quantitative and microstructural imaging, though the technology remains a work in progress rather than a cleared

Top Growth Drivers of the Cutaneous Squamous Cell Carcinoma Market
• AI-assisted bone-lesion detection is transitioning from research into regulated clinical products, with dedicated algorithms now capable of automatically identifying and localizing suspicious bone lesions on CT imaging.
• Sarcoma classification is moving from morphology-based assessment toward molecular and fusion-based diagnosis, particularly for Ewing sarcoma and related round-cell sarcomas.
• Liquid biopsy research is expanding into prospective, multi-site studies evaluating ctDNA for diagnosis, prognosis, and recurrence monitoring in bone and soft-tissue sarcomas.
• Whole-body and combined-modality imaging platforms, including total-body PET/CT and PET/MR systems, are advancing toward faster acquisition times and reduced radiation exposure.
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/bone-cancer-diagnosis-market?akash

Market Segmentation
By Cancer Type
• Osteosarcoma
• Chondrosarcoma
• Ewing Sarcoma
• Chordoma
• Others
Osteosarcoma generates the largest share of diagnostic-market revenue at an estimated 34.2%, reflecting its intensive diagnostic pathway of MRI, chest CT, biopsy, and metastatic staging, while chondrosarcoma (27.1%) and Ewing sarcoma (21.4%) follow, with Ewing sarcoma standing out for its growing reliance on molecular fusion testing.
By Diagnosis Type
• MRI
• CT
• X-ray
• PET/CT & Bone Scan
• Biopsy & Histopathology
MRI leads all diagnostic modalities with an estimated 29.8% share of 2025 market revenue, owing to its ability to assess bone marrow and soft-tissue involvement without ionizing radiation, while biopsy and histopathology (19.7%) are gaining relevance as sarcoma classification becomes more dependent on molecular confirmation.
By End-User
• Hospitals
• Diagnostic Centers
• Cancer Research Centers
• Others
Hospitals account for the largest end-user share at an estimated 49.5%, reflecting the need to coordinate imaging, biopsy, pathology, anesthesia, and specialist orthopedic oncology under one setting, while independent and hospital-affiliated diagnostic imaging centers hold 31.8%.
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
North America holds the largest regional share at an estimated 38.6% of global bone cancer diagnostic revenue, supported by advanced imaging infrastructure and specialist sarcoma centers, while Asia-Pacific is identified as the fastest-growing region as diagnostic infrastructure continues to expand.

Competitive Landscape
Top Five Key Players
• Siemens Healthineers
• GE HealthCare
• Philips
• Guerbet and Intrasense
• Canon Medical Systems
Siemens Healthineers: Siemens Healthineers maintains a broad position across MRI, CT, digital X-ray, PET/CT, and PET/MR, and received FDA clearance in January 2026 for its second-generation Biograph One PET/MR platform, which combines anatomical and metabolic imaging with AI-based reconstruction and workflow automation.
GE HealthCare: GE HealthCare competes across MRI, CT, PET/CT, SPECT/CT, and advanced visualization, and its Omni 128 cm total-body PET/CT, which received CE marking in November 2025, is designed to improve whole-body cancer diagnosis and staging through higher-sensitivity imaging and shorter acquisition times.
Guerbet and Intrasense: Guerbet and Intrasense occupy a differentiated software position through DUOnco Bone, a CE-marked AI system that automatically detects and localizes suspicious bone lesions on CT examinations, representing one of the clearest dedicated commercial AI propositions in bone-lesion interpretation.
Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/bone-cancer-diagnosis-market?akash

Regional Analysis
Europe is estimated to account for 27.4% of global bone cancer diagnostic revenue in 2025, equivalent to around USD 363 million, positioning it as the second-largest regional market in the report. The region combines mature radiology infrastructure with established sarcoma referral networks and broad access to MRI and pathology services. Germany represents the largest modeled European country market at an estimated 5.3% of global revenue, followed by the United Kingdom at 4.6% and France at around 4.1%, with Italy and Spain contributing smaller shares.
Europe is also becoming an important commercialization market for AI-assisted lesion detection, reflected in the CE marking of Guerbet and Intrasense's DUOnco Bone and GE HealthCare's total-body PET/CT system. According to the DataM Intelligence report, North America is the dominant regional market at an estimated 38.6% share, while Asia-Pacific is identified as the fastest-growing region, supported by expanding MRI and CT installation and improving oncology referral pathways.

Conclusion
The global bone cancer diagnosis market is expected to experience robust growth over the forecast period, driven by increasing demand for advanced diagnostic solutions. Growth is being shaped less by rising case volumes, since primary bone cancer remains rare, and more by the increasing diagnostic intensity required per case, spanning imaging, biopsy, pathology, and molecular testing. MRI continues to anchor the diagnostic pathway, while AI-assisted lesion detection and fusion-based molecular classification, particularly for Ewing sarcoma, are adding new layers of commercial value.
The competitive landscape is led by multimodality imaging companies such as Siemens Healthineers, GE HealthCare, and Philips, alongside a more differentiated AI-software position held by Guerbet and Intrasense. Regionally, North America retains the largest share of the market, Europe holds a substantial secondary position anchored by Germany, the UK, and France, and Asia-Pacific is expected to grow the fastest as imaging and oncology infrastructure continues to expand. Together, these dynamics point to a diagnostic market that is becoming increasingly technology-layered even as the underlying disease it addresses remains uncommon.
Unlock Complete Market Intelligence with the Full Report: https://www.datamintelligence.com/buy-now-page?report=bone-cancer-diagnosis-market?akash

Industry Related Reports:
Point-of-Care Ultrasound Market
The global Point-of-Care Ultrasound Market reached USD 2.35 billion in 2025 and is expected to reach USD 4.60 billion by 2033, growing at a CAGR of 8.8% during 2026-2033. Rising demand for portable imaging, AI-assisted diagnostics, and bedside ultrasound solutions is driving market growth across hospitals, emergency care, and remote healthcare settings.
Explore the Full Market Report: https://www.datamintelligence.com/research-report/point-of-care-ultrasound-market?akash

AI in Medical Imaging Market
The global AI in Medical Imaging Market reached USD 1.97 billion in 2025 and is projected to reach USD 17.50 billion by 2035, growing at a CAGR of 24.60% during the forecast period. Increasing adoption of AI-powered diagnostic tools, rising imaging workloads, and the need for faster, more accurate clinical decision-making are accelerating market expansion.
Unlock Comprehensive Market Intelligence: https://www.datamintelligence.com/research-report/ai-in-medical-imaging-market?akash

Get More Japan Market Insights: https://www.datamintelligence.com/jp-market-research-report?akash

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.